Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report
Clinical Transplantation · 2026-06 · 40 (6)
DOI: 10.1111/ctr.70587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 12.06.2026. Verfasst von Alex Ng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Alemtuzumab, Kidney Transplantation, Graft Survival, Graft Rejection. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The effects of induction therapy with the anti‐CD52 monoclonal antibody alemtuzumab on age‐specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single‐dose alemtuzumab induction in deceased donor (DD) KT recipients according to different recipient age groups.
Methods
Single‐center retrospective nonrandomized cohort review of DDKT recipients stratified by age (30–49/50–69/70 years). All patients received a single 30‐mg intra‐operative dose of alemtuzumab. Standardized management algorithms were used. All patients received triple maintenance immunosuppression with tacrolimus/mycophenolate/steroids.
Results
From September 2012 to December 2018, 723 DDKTs were performed with alemtuzumab induction. Donor age (33.1 ± 15.7 vs. 47.3 ± 16.0 vs. 53.3 ± 13.4 years; p < 0.001) and kidney donor profile index (KDPI, 46.5 ± 25.1 vs. 65.5 ± 23.8 vs. 74.4 ± 20.5%; p < 0.001) increased with increasing recipient age groups. Overall patient ( p < 0.001) and graft ( p < 0.001) but not death‐censored graft survival ( p = 0.6) rates decreased with increasing recipient age strata. Rates of delayed graft function, biopsy‐proven acute rejection, and infectious complications at 1‐year post‐transplant were comparable amongst groups.
Conclusion
In DDKT recipients, alemtuzumab induction does not appear to confer excess risk of graft failure, acute rejection, or short‐term infectious complications in older patients relative to younger counterparts in the setting of triple maintenance immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
- Surgery, Section of Transplantation, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Internal Medicine, Section of Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
ORCID-Profile: Alex Ng, David I Harriman, Alan C Farney, Giuseppe Orlando, Colleen Jay, Robert J Stratta
Zitieren
APA
Ng, A., Harriman, D. I., Farney, A. C., Orlando, G., Jay, C., Reeves-Daniel, A., & Stratta, R. J. (2026). Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report. Clinical Transplantation, 40(6). https://doi.org/10.1111/ctr.70587
Vancouver
Ng A, Harriman DI, Farney AC, Orlando G, Jay C, Reeves-Daniel A, et al. Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report. Clinical Transplantation. 2026;40(6). doi:10.1111/ctr.70587
BibTeX
@article{Ng2026,
author = {Ng, Alex and Harriman, David I and Farney, Alan C and Orlando, Giuseppe and Jay, Colleen and Reeves-Daniel, Amber and Stratta, Robert J},
title = {Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {6},
doi = {10.1111/ctr.70587}
}
EUVIMED